Single-dose intravenous iron for iron deficiency: A new paradigm

Hematology

Volumn 2016, Issue 1, 2016, Pages 57-66

  Auerbach, Michael ^a,b   Deloughery, Thomas ^c,d  

^a Georgetown University School of Medicine ^*  (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Laboratory Medicine   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ACUTE DISEASE; ALTITUDE DISEASE; ARTICLE; BARIATRIC SURGERY; CONSENSUS; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; SINGLE DRUG DOSE; UTERUS BLEEDING; ALTITUDE SICKNESS; ANEMIA, IRON-DEFICIENCY; BLOOD; FEMALE; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; MALE; PREGNANCY COMPLICATIONS, HEMATOLOGIC; UTERINE HEMORRHAGE;

ADMINISTRATION, INTRAVENOUS; ALTITUDE SICKNESS; ANEMIA, IRON-DEFICIENCY; BARIATRIC SURGERY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RESTLESS LEGS SYNDROME; UTERINE HEMORRHAGE;

EID: 85012085243     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2016.1.57     Document Type: Article

References (72)

1. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13(12): 1545-1553.
2. Jimenez K, Gasche C, Auerbach M. On both sides of the ocean. Blood Transfus (Italy). 2016; DOI 10.2450/2016.0304-15.
3. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015; 10(2): e0117383.
4. Schrier S, Auerbach M. Treatment of Anemia due to iron deficiency. In: UpToDate, Tirnauer J (Ed), 2016.
5. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011; 12(9): 906-913.
6. Ondo WG Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med. 2010; 11(5): 494-496.
7. Talbot NP, Smith TG, Privat C, et al. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol. 2011; 12(3): 265-269.
8. Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Canc Netw. 2014; 12(5): 657-664.
9. Wysowski DK, Swartz L, Borders-Hemphill BV, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85(9): 650-654.
10. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016; 91(1): 31-38.
11. Baird IM, Podmore DA. Intramuscular iron therapy in iron-deficiency anaemia. Lancet. 1954; 267(6845): 942-946.
12. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008; 83(7): 580-588.
13. Kanakaraddi VP, Hoskatti CG, Nadig VS, Patil CK, Maiya M. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. J Assoc Physicians India. 1973; 21(10): 849-853.
14. Varde KN Treatment of 300 cases of iron deficiency of pregnancy by total dose infusion of iron-dextran complex. J Obstet Gynaecol Br Commonw. 1964; 71: 919-922.
15. Marchasin S, Wallerstein RO. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood. 1964; 23: 354-358.
16. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980; 243(17): 1726-1731.
17. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989; 321(3): 158-163.
18. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26(1): 41-46.
19. Michael B, Coyne DW, Fishbane S, et al.; Ferrlecit Publication Committee. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int. 2002; 61(5): 1830-1839.
20. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21(2): 378-382.
21. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007; 29(4): 423-426.
22. Moniem K, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med. 2007; 9: 37-42.
23. Critchley J, Dunbar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): A systematic review. Transfus Altern Transfus Med. 2007; 9: 8-36.
24. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014; 9(4): 705-712.
25. Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012; 87(11): E123-E124.
26. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015; 90(1): 12-23.
27. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015; 314(19): 2062-2068.
28. DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron?-Unconvincing data from an unconvincing study. Am J Hematol. 2016; 91(5): 451-452.
29. Macdougall IC, Bircher AJ, Eckardt KU, et al.; Conference Participants. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016; 89(1): 28-39.
30. Barton JC, Barton EH, Bertoli LF, Gothard CH, Sherrer JS. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med. 2000; 109(1): 27-32.
31. Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica. 2015; 100(5): e214-e215.
32. Andrews N. Disorders of iron metabolism. 1999; 341: 1986-1995.
33. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol. 2011; 86(10): 860-862.
34. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007; 369(9572): 1502-1504.
35. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy and safety. Hematol Am Soc Hematol Educ Program. 2010; 2010: 338-347.
36. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014; 99(11): 1671-1676.
37. Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol. 2011; 4(4): 399-406.
38. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78(3): 480-491.
39. Bircher AJ, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am. 2014; 34(3): 707-723, x-xi.
40. Auerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. Am J Hematol. 2013; 88(11): 944-947.
41. Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010; 90(7): 804-805.
42. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013; 24(2): 475-482.
43. Evstatiev R, Marteau P, Iqbal T, et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011; 141(3): 846-853.e1, 2.
44. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009; 49(12): 2719-2728.
45. Myers B, Myers A, Moore J. Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron(III) hydroxide dextran (Cosmofer) in pregnancy. Obstet Med. 2012; 5: 105-107.
46. Muñoz M, Gómez-Ramírez S, Cuenca J, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion. 2014; 54(2): 289-299.
47. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016; 9: 53-64.
48. Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr. 2012; 160(6): 1027-1033.
49. Chang S, Zeng L, Brouwer ID, Kok FJ, Yan H. Effect of iron deficiency anemia in pregnancy on child mental development in rural China. Pediatrics. 2013; 131(3): e755-e763.
50. Reveiz L, Gyte G, Cuervo L, et al. Treatments for iron-deficiency aneaemia in pregnancy. The Cochrane Collaboration. Oxford, UK: Wiley and Sons; 2012
51. Hanieh S, Ha TT, Simpson JA, et al. The effect of intermittent antenatal iron supplementation on maternal and infant outcomes in rural Viet Nam: a cluster randomised trial. PLoS Med. 2013; 10(6): e1001470.
52. Ayub R, Tariq N, Adil MM, Iqbal M, Junaid A, Jaferry T. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008; 18(7): 424-427.
53. Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012; 40(5): 469-474.
54. Wong L, Smith S, Gilstrop M, et al. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. Am J Hematol. 2016; 91(6): 590-593.
55. Salgado W Jr, Modotti C, Nonino CB, Ceneviva R. Anemia and iron deficiency before and after bariatric surgery. Surg Obes Relat Dis. 2014; 10(1): 49-54.
56. Obinwanne KM, Fredrickson KA, Mathiason MA, Kallies KJ, Farnen JP, Kothari SN. Incidence, treatment, and outcomes of iron deficiency after laparoscopic Roux-en-Y gastric bypass: a 10-year analysis. J Am Coll Surg. 2014; 218(2): 246-252.
57. Muñoz M, Botella-Romero F, Gómez-Ramírez S, Campos A, García-Erce JA. Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management. Nutr Hosp. 2009; 24(6): 640-654.
58. Malone M, Barish C, He A, Bregman D. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg. 2013; 23(9): 1413-1420.
59. Strauss W, DeBusk K, Barish C, et al. Randomized, placebo-controlled evaluation of ferumoxytol treatment for iron deficiency anemia in patients who have a history of unsatisfactory oral iron therapy: fatigue and health-related quality of life in gastric bypass patient. Published abstract presented at the Obesity Society's 31st annual scientific meeting, November, 2013, Atlanta, GA.
60. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004; 53(8): 1190-1197.
61. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40(9): 1058-1065.
62. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2016; gutjnl-2015-309940. (in press)
63. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008; 103(5): 1182-1192.
64. Teitelbaum J. Nutritional deficiencies in inflammatory bowel disease. In: UpToDate Rutgeerts, Lipman Motil (Eds), 2016.
65. García-López S, Bocos JM, Gisbert JP, et al. High-dose intravenous treatment in iron deficiency anemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus. 2016; 14(2): 199-205.
66. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005; 165(11): 1286-1292.
67. Allen RP, Barker PB, Wehrl FW, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001; 56(2): 263-265.
68. Rizzo G, Manners D, Testa C, et al. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Mov Disord. 2013; 28(13): 1886-1890.
69. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998; 21(4): 371-377.
70. Mehmood T, Auerbach M, Earley CJ, Allen RP. Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). Sleep Med. 2014; 15(12): 1473-1476.
71. Camaschella C. The Ham Wasserman Lecture. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013; 2013: 1-8.
72. Smith TG, Balanos GM, Croft QP, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008; 586(24): 5999-6005.